Abivax S.A.: Share Price Multiplier Effect Following Phase 3 Study Data for Obefazimod - Experts React With Enormous Price Target Increases!

Abivax achieved a significant milestone on July 22 with the announcement of positive Phase 3 results from the two ABTECT induction studies (ABTECT-1 and ABTECT-2) for Obefazimod. The orally administered, first-in-class miR-124 enhancer demonstrated a placebo-adjusted clinical remission rate of 16.4% in week 8 at a 50 mg dose in patients with moderate to severe active ulcerative colitis, thereby meeting the FDA's primary endpoint. Ulcerative colitis is a chronic inflammation of the colon, specifically the inner mucosa. It is an autoimmune condition...